Furthermore, these studies indicate that tyrosine kinase inhibitors, now used broadly in cancer therapies, may change cardiac function by directly modifying the heart’s tyrosine kinase and serine/threonine kinase profiles. The gene discussed is MARK2; the disease is cancer.